Gross Profit Comparison: Vertex Pharmaceuticals Incorporated and Takeda Pharmaceutical Company Limited Trends

Vertex vs. Takeda: A Decade of Profit Growth

__timestampTakeda Pharmaceutical Company LimitedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 20141256834000000519428000
Thursday, January 1, 20151271973000000906794000
Friday, January 1, 201611732960000001491717000
Sunday, January 1, 201712746100000002213533000
Monday, January 1, 201814375340000002638058000
Tuesday, January 1, 201922014240000003615063000
Wednesday, January 1, 202022035040000005469383000
Friday, January 1, 202124621600000006670200000
Saturday, January 1, 202227834060000007850400000
Sunday, January 1, 202328322570000008607000000
Monday, January 1, 202428322570000009489600000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Pharmaceutical Giants: Vertex vs. Takeda

Gross Profit Trends from 2014 to 2023

In the ever-evolving pharmaceutical industry, Vertex Pharmaceuticals Incorporated and Takeda Pharmaceutical Company Limited have showcased distinct trajectories in their gross profit trends over the past decade. From 2014 to 2023, Takeda's gross profit has seen a robust growth of approximately 125%, peaking at 2.83 trillion in 2023. This reflects Takeda's strategic expansions and acquisitions, solidifying its position as a global leader.

Conversely, Vertex Pharmaceuticals, a pioneer in cystic fibrosis treatments, has experienced a remarkable 1,557% increase in gross profit, reaching 8.61 billion in 2023. This surge underscores Vertex's innovative breakthroughs and market penetration.

While Takeda's financial journey is marked by consistent growth, Vertex's trajectory highlights its rapid ascent in the biotech sector. Notably, data for 2024 is incomplete, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025